-David A Cooper Researcher Activity Profile

Research Author Detailed Information 

David A Cooper Publication Rate By Year

David A Cooper has published 1 paper(s) in 1949, 2 paper(s) in 2006, 9 paper(s) in 2007, 4 paper(s) in 2008, for a total of 16 research publications in total.

David A Da Cooper Author Information

LAST NAME: cooper

FIRST NAME: David A

INITIALS: da

AFFILIATION:

Papers

David A Cooper's Publication Record

1. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Year Published: 2006
2. Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. Year Published: 2006
Partners AIDS Research Center, MGH-East, CNY 6616, 149 13th Street, Charlestown, MA 02129, USA.
3. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. Year Published: 2007
National Centre in HIV Epidemiology and Clinical Research, the University of New South Wales, Sydney, Australia.
4. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Year Published: 2007
From the aNational Centre in HIV Epidemiology and Clinical Research, Australia bSchool of Mathematics and Statistics, University of New South Wales, Sydney, Australia cMerck Research Laboratories, North Wales, Pennsylvania, USA.
5. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Year Published: 2007
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia.
6. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. Year Published: 2007
National Centre in HIV Epidemiology and Clinical Research, the University of New South Wales, Sydney, Australia.
7. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Year Published: 2007
National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW 2052, Australia. J.Murray@unsw.edu.au
8. Peripheral vascular disease in the lungs. Year Published: 1949
9. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Year Published: 2007
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia.
10. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. Year Published: 2008
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia. dcarey@nchecr.unsw.edu.au
11. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. Year Published: 2007
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. milos.opravil@usz.ch
12. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Year Published: 2007
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia.
13. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. Year Published: 2008
National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia. dcarey@nchecr.unsw.edu.au
14. Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Year Published: 2008
The HIV-Netherlands Australia Thailand Research Collaboration - Thai Red Cross AIDS Research Center, Bangkok, Thailand.
15. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. Year Published: 2007
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland. milos.opravil@usz.ch
16. Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. Year Published: 2008
St Vincent's Hospital, Sydney, Australia. acalmy@gmail.com